title: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
abstract: Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
authors.affiliation: Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Bibiana
authors.initials: B
authors.lastname: Bielekova
authors.forename: Nancy
authors.initials: N
authors.lastname: Richert
authors.forename: Thomas
authors.initials: T
authors.lastname: Howard
authors.forename: Gregg
authors.initials: G
authors.lastname: Blevins
authors.forename: Silva
authors.initials: S
authors.lastname: Markovic-Plese
authors.forename: Jennifer
authors.initials: J
authors.lastname: McCartin
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Frank
authors.forename: Jens
authors.initials: J
authors.lastname: Würfel
authors.forename: Joan
authors.initials: J
authors.lastname: Ohayon
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Waldmann
authors.forename: Henry F
authors.initials: HF
authors.lastname: McFarland
authors.forename: Roland
authors.initials: R
authors.lastname: Martin
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D011994:Recombinant Proteins
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007370:Interferon Type I; D011994:Recombinant Proteins; D000077561:Daclizumab